Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by BioAge Labs, Inc.

BioAge Labs Announces First Participant Dosed in Phase 1 Clinical Trial of BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor
From BioAge Labs, Inc.
Via GlobeNewswire
Tickers BIOA
BioAge Labs Reports Second Quarter 2025 Financial Results and Provides Business Updates
From BioAge Labs, Inc.
Via GlobeNewswire
Tickers BIOA
BioAge Labs to Present Preclinical Data on APJ Agonism for Diabetic Obesity and Heart Failure at the American Diabetes Association (ADA) 85th Scientific Sessions
From BioAge Labs, Inc.
Via GlobeNewswire
Tickers BIOA
BioAge Labs Expands Drug Discovery Platform with Data from Leading European Biobank
From BioAge Labs, Inc.
Via GlobeNewswire
Tickers BIOA
BioAge Expands APJ Agonist Pipeline with Oral Small-Molecule and Long-Acting Biologic Candidates
From BioAge Labs, Inc.
Via GlobeNewswire
Tickers BIOA
BioAge Labs completes IND-enabling studies for BGE-102, a potent, orally available, brain-penetrant NLRP3 inhibitor, and advances candidate toward the clinic
From BioAge Labs, Inc.
Via GlobeNewswire
Tickers BIOA
BioAge Labs to Present at Upcoming Investor Conferences
From BioAge Labs, Inc.
Via GlobeNewswire
Tickers BIOA
BioAge Labs Reports First Quarter 2025 Financial Results and Provides Business Updates
From BioAge Labs, Inc.
Via GlobeNewswire
Tickers BIOA
BioAge Labs Reports Full Year 2024 Financial Results and Provides Business Updates from the Fourth Quarter of 2024
From BioAge Labs, Inc.
Via GlobeNewswire
Tickers BIOA
BioAge Labs to Participate in TD Cowen's 45th Annual Health Care Conference
From BioAge Labs, Inc.
Via GlobeNewswire
Tickers BIOA
BioAge Labs Announces Company Updates on APJ, NLRP3, and Platform Programs
From BioAge Labs, Inc.
Via GlobeNewswire
Tickers BIOA
BioAge Labs Announces Multi-Year Collaboration with Novartis to Discover Novel Targets for Therapies that Address Age-Related Diseases and Conditions
From BioAge Labs, Inc.
Via GlobeNewswire
Tickers BIOA
BioAge Labs Announces Discontinuation of STRIDES Phase 2 Clinical Trial Evaluating Azelaprag in Combination with Tirzepatide for the Treatment of Obesity
From BioAge Labs, Inc.
Via GlobeNewswire
Tickers BIOA
BioAge Labs to Present at Goldman Sachs “Year-Ahead” Catalyst Clinic
From BioAge Labs, Inc.
Via GlobeNewswire
Tickers BIOA
BioAge Labs to Present at Upcoming Investor Conferences
From BioAge Labs, Inc.
Via GlobeNewswire
Tickers BIOA
BioAge Labs Reports Third Quarter 2024 Financial Results and Provides Business Updates
From BioAge Labs, Inc.
Via GlobeNewswire
Tickers BIOA
BioAge Labs to Present Preclinical Data for APJ Agonist Azelaprag at ObesityWeek 2024
From BioAge Labs, Inc.
Via GlobeNewswire
Tickers BIOA
BioAge Labs to Present at Jefferies London Healthcare Conference
From BioAge Labs, Inc.
Via GlobeNewswire
Tickers BIOA
BioAge Labs Announces Closing of Initial Public Offering, Full Exercise of Underwriters’ Option to Purchase Additional Shares and Closing of the Concurrent Private Placement
From BioAge Labs, Inc.
Via GlobeNewswire
Tickers BIOA
BioAge Labs Announces Pricing of Upsized Initial Public Offering
From BioAge Labs, Inc.
Via GlobeNewswire
BioAge Appoints Former GSK CEO Jean-Pierre Garnier as Chair of Its Board of Directors
From BioAge Labs, Inc.
Via Business Wire
BioAge Labs Presents Preclinical Data for Apelin Receptor Agonist Azelaprag for Obesity Demonstrating Significant Improvements in Weight Loss and Body Composition When Combined with Incretin Drugs
From BioAge Labs, Inc.
Via Business Wire
BioAge Labs Announces Inaugural Scientific Advisory Board to Support Advancement of Novel Therapeutics Targeting Metabolic Aging
From BioAge Labs, Inc.
Via Business Wire
BioAge Appoints Renowned Cardiologist and Biopharma Entrepreneur Michael H. Davidson, MD, to its Board of Directors
From BioAge Labs, Inc.
Via Business Wire
BioAge Labs Announces Plans for Phase 2 Trial of First-in-Class Apelin Receptor Agonist BGE-105/Azelaprag Co-Administered With Tirzepatide for Treatment of Obesity, in Collaboration With Lilly’s Chorus Organization
From BioAge Labs, Inc.
Via Business Wire
BioAge Labs Appoints BJ Sullivan as Chief Strategy Officer
From BioAge Labs, Inc.
Via Business Wire
BioAge Labs to Present on Therapeutics for Brain Aging Targeting NLRP3, Apelin, and Other Novel Pathways at Upcoming International Conferences
From BioAge Labs, Inc.
Via Business Wire
BioAge Hosting Webcast to Discuss Newly Announced Phase 1b Data Demonstrating BGE-105 Significantly Improves Muscle Atrophy in Older Volunteers on Bed Rest and Detail Phase 2 Plans
From BioAge Labs, Inc.
Via Business Wire
BioAge Announces Positive Topline Results for BGE-105 in Phase 1b Clinical Trial Evaluating Muscle Atrophy in Older Volunteers at Bed Rest
From BioAge Labs, Inc.
Via Business Wire
BioAge Labs to Present Data on Novel Brain-Penetrant NLRP3 Inhibitors for Treatment of Neurodegeneration and Brain Aging at Upcoming Conferences
From BioAge Labs, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.